ConductScience.org, home

Paper1494073

Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.

Ginsberg GM and 1 other. J Epidemiol Community Health, 1992. Cited by 31 papers, by iCite.

Cite this record

ConductScience Library. Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity. Papers, record 1494073. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1494073

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Cost-benefit analysis of a nationwide neonatal inoculation programme against hepatitis B in an area of intermediate endemicity.
PubMed
Journal
J Epidemiol Community Health
PubMed
Year
1992
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
31
iCite
Relative citation ratio, by iCite
1.38
iCite
Revised in PubMed
2019-05-03
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ginsberg GMG M
2Shouval DD

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hepatitis BMajor topic
Hepatitis B VaccinesMajor topic
ImmunizationMajor topic
Cost-Benefit Analysis
Humans
Incidence
Infant, Newborn
Israel

Source PubMed

Download CSV of topics

References58

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
13723115Perinatal transmission of hepatitis B virus in Kenya: its relation to the presence of serum HBV-DNA and anti-HBe in the mother.J Med Virol1986https://conductscience.org/library/papers/3723115PubMed
23192122[Infectious disease morbidity in Kibbutzim].Harefuah1988https://conductscience.org/library/papers/3192122PubMed
34118686Natural history of hepatitis-associated antigen-positive chronic liver disease.Lancet1972https://conductscience.org/library/papers/4118686PubMed
44153785Posthepatitis syndromes.Clin Gastroenterol1974https://conductscience.org/library/papers/4153785PubMed
54315927Viral hepatitis in Israel: morbidity and mortality data.Am J Epidemiol1970https://conductscience.org/library/papers/4315927PubMed
64608655Chronic viral hepatitis.Clin Gastroenterol1974https://conductscience.org/library/papers/4608655PubMed
76109938Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).Lancet1981https://conductscience.org/library/papers/6109938PubMed
86118576Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan.Lancet1981https://conductscience.org/library/papers/6118576PubMed
96126411Viral hepatitis during pregnancy in Israel.Int J Gynaecol Obstet1982https://conductscience.org/library/papers/6126411PubMed
106138642Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine.Lancet1983https://conductscience.org/library/papers/6138642PubMed
116229201Hepatitis B vaccine. Health and Public Policy Committee, American College of Physicians.Ann Intern Med1984https://conductscience.org/library/papers/6229201PubMed
126262862Hepatitis B infection and primary liver cancer.Prog Med Virol1981https://conductscience.org/library/papers/6262862PubMed
136264023Hepatitis A antibody in Israel Defence Forces recruits.J Med Virol1981https://conductscience.org/library/papers/6264023PubMed
146277763Primary hepatocellular carcinoma--etiology, pathogenesis, and prevention.Hum Pathol1981https://conductscience.org/library/papers/6277763PubMed
156293033Persistent infection of humans with hepatitis B virus: mechanisms and consequences.Rev Infect Dis1982https://conductscience.org/library/papers/6293033PubMed
166339349Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial.Hepatology1983https://conductscience.org/library/papers/6339349PubMed
176405916Should homosexuals be vaccinated against hepatitis B virus? Cost and benefit assessment.Br Med J (Clin Res Ed)1983https://conductscience.org/library/papers/6405916PubMed
186434124Indications for hepatitis B immunoglobulin for neonates of HBsAg carrier mothers.Br Med J (Clin Res Ed)1984https://conductscience.org/library/papers/6434124PubMed
196747609Detection and characterization of hepatitis B virus DNA in serum of HBe antigen-negative HBsAg carriers.J Med Virol1984https://conductscience.org/library/papers/6747609PubMed
206805749Acute viral hepatitis B: laboratory reports 1975-9.Br Med J (Clin Res Ed)1982https://conductscience.org/library/papers/6805749PubMed

See all 58 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.

PMIDTitleJournalYearIn PapersSource
39591157Hepatitis B Virus-Related Cirrhosis and Hepatocellular Carcinoma Hospital Discharge Rates from 2005 to 2021 in Spain: Impact of Universal Vaccination.Vaccines (Basel)2024https://conductscience.org/library/papers/39591157PubMed
35632549The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma.Vaccines (Basel)2022https://conductscience.org/library/papers/35632549PubMed
31656166Clinical practice guideline management of blood borne viruses within the haemodialysis unit.BMC Nephrol2019https://conductscience.org/library/papers/31656166PubMed
25132754Hepatitis B vaccine by intradermal route in non responder patients: an update.World J Gastroenterol2014https://conductscience.org/library/papers/25132754PubMed
23326280Hepatitis B vaccination in chronic kidney disease: review of evidence in non-dialyzed patients.Hepat Mon2012https://conductscience.org/library/papers/23326280PubMed
22077578Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.Pharmacoeconomics2011https://conductscience.org/library/papers/22077578PubMed
10174324Cost-benefit analysis of riluzole for the treatment of amyotrophic lateral sclerosis.Pharmacoeconomics1997https://conductscience.org/library/papers/10174324PubMed
10155330Cost-effectiveness analysis of hepatitis B vaccination strategies in Catalonia, Spain.Pharmacoeconomics1995https://conductscience.org/library/papers/10155330PubMed
10146907Hepatitis B vaccine: a pharmacoeconomic evaluation of its use in the prevention of hepatitis B virus infection.Pharmacoeconomics1994https://conductscience.org/library/papers/10146907PubMed
8154573A cost-benefit analysis of legislation for bicycle safety helmets in Israel.Am J Public Health1994https://conductscience.org/library/papers/8154573PubMed
8120505Cost benefit analysis of Haemophilus influenzae type b vaccination programme in Israel.J Epidemiol Community Health1993https://conductscience.org/library/papers/8120505PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1494073

GET https://conductscience.org/api/papers/v1/1494073/references?page=2